Drug Profile


Alternative Names: AKCEA-APOCIII-LRx; GalNAc3 conjugated antisense oligonucleotide - Ionis Pharmaceuticals; IONIS-APOCIII-LRx; ISIS-APOCIII-LRx

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Akcea Therapeutics; Ionis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action Apolipoprotein C-III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypertriglyceridaemia

Most Recent Events

  • 06 Nov 2017 Akcea plans a phase IIb dose-ranging study for Hypertriglyceridemia in patients with established cardiovascular disease in the second half of 2017
  • 31 Oct 2017 Safety and efficacy data from a phase I trial in Hypertriglyceridaemia released by Akcea Therapeutics
  • 06 Jan 2017 Ionis Pharmaceuticals, Akcea Therapeutics and Novartis enter into an optional licensing agreement to co-promote and co-develop AKCEA-APOCIII-LRx for Hyperlipoproteinaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top